King Pharma Says Patent Deal Didn't Bar Skelaxin Generic
Pfizer Inc. unit King Pharmaceuticals Inc. on Friday said that, contrary to complaints, a patent licensing agreement related to its Skelaxin drug, now the subject of multidistrict antitrust litigation in Tennessee,...To view the full article, register now.
Already a subscriber? Click here to view full article